Table 1 Characteristics of the COVID-19 patients
Total population n = 545 | Peak analysis n = 328 | Decay analysis n = 194 | 6-month visit n = 197 | |
|---|---|---|---|---|
Age, year, Mean ± sd | 50.9 ± 15.0 | 49.9 ± 14.5 | 52.2 ± 13.9 | 55.9 ± 13.3 |
Age, N(%) | ||||
18 ~ 40 year | 140 (25.7%) | 88 (26.8%) | 41 (21.1%) | 28 (14.2%) |
41 ~ 60 year | 262 (48.1%) | 159 (48.5%) | 98 (50.5%) | 93 (47.2%) |
61 ~ 90 year | 143 (26.2%) | 81 (24.7%) | 55 (28.4%) | 76 (38.6%) |
Gender, N (%) | ||||
female | 259 (47.5%) | 155 (47.3%) | 86 (44.3%) | 92 (46.7%) |
male | 286 (52.5%) | 173 (52.7%) | 108 (55.7%) | 105 (53.3%) |
Disease severitya, N (%) | ||||
mild | 491 (90.1%) | 304 (92.7%) | 181 (93.3%) | 181 (91.9%) |
severe | 54 (9.9%) | 24 (7.3%) | 13 (6.7%) | 16 (8.1%) |
Number of antibody testing, N (%) | ||||
1 | 166 (30.5%) | 26 (7.9%) | 0 (0%) | 26 (13.2%) |
2 | 111 (20.4%) | 76 (23.2%) | 31 (16.0%) | 24 (12.2%) |
3 | 144 (26.4%) | 126 (38.4%) | 87 (44.8%) | 76 (38.6%) |
≥4 | 124 (22.8%) | 100 (30.5%) | 76 (39.2%) | 71 (36.0%) |
Number of RT-PCR testing, Mean ± sd | 7.0 ± 2.3 | 7.3 ± 2.2 | 7.2 ± 2.1 | 6.9 ± 2.1 |
Days from symptom to PCR positiveb, Mean ± sd | 11.7 ± 8.4 | 12.6 ± 8.1 | 13.1 ± 8.1 | 12.3 ± 8.0 |
Duration of COVID-19c, day, Mean ± sd | 25.6 ± 13.1 | 26.8 ± 12.6 | 29.8 ± 12.4 | 28.7 ± 13.2 |
Length of follow upd, days | 62 (45, 175) | 63 (49, 179) | 174 (62, 183) | 180 (174, 184) |
Use of hydroxychloroquinee, N (%) | 49 (13.5%) | 39 (14.1%) | 22 (12.8%) | 21 (15.1%) |
Use of glucocorticoidse, N (%) | 178 (48.9%) | 135 (48.9%) | 90 (52.3%) | 79 (56.8%) |
